Messenger RNA (mRNA) is the molecule that carries a recipe from a cell’s genetic blueprint to the cell’s protein-making machinery, telling it which proteins to build and when. Investors care because mRNA can be used as a flexible platform to develop drugs and vaccines quickly—like swapping recipes in a kitchen—which affects a company’s potential market size, manufacturing needs, regulatory review, and revenue prospects.
self-amplifying messenger RNAmedical
Self-amplifying messenger RNA (sa-mRNA) is a laboratory-designed strand of RNA that, in addition to carrying instructions to make a target protein, also encodes a small set of viral replication enzymes so those instructions can be copied inside a cell. Like a message that brings its own photocopier, sa-mRNA can produce more protein from a smaller initial dose, which matters to investors because it can affect manufacturing scale, dosing, cost, and the commercial potential of RNA-based vaccines and therapies.
small interfering RNAmedical
Small interfering RNA (siRNA) are short, lab-made strands of genetic material that act like a mute button inside cells, binding to a specific genetic message and preventing a particular protein from being made. For investors, siRNA represents a drug technology with the potential to treat diseases by precisely turning off harmful genes, which can mean high development costs, regulatory hurdles, intellectual property value, and the possibility of breakthrough therapies that change market dynamics.
circular RNAmedical
A circular RNA is a naturally occurring molecule of genetic material shaped into a closed loop rather than a line, which makes it more stable inside cells. It can affect how genes are turned on or off and can serve as a durable marker or target for new diagnostics and therapies. Investors care because circular RNAs can create opportunities for novel drugs, more precise tests, and potentially valuable intellectual property in biotech portfolios.
antisense RNAmedical
Short strands of RNA that are designed or occur naturally to stick to a matching messenger RNA sequence in a cell, blocking or altering the process that turns that message into a protein. For investors, antisense RNA represents a class of therapeutic technology that can create targeted medicines, influence clinical trial outcomes, affect patent and regulatory timelines, and therefore impact the value of companies developing or licensing these therapies; think of it as placing a temporary cover on a blueprint to prevent a factory from making a specific part.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SAN DIEGO--(BUSINESS WIRE)--
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts:
Webcast link can be found under Investor Relations/Events section of Arcturus’ website.
About Arcturus
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for pandemic flu and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. Please connect with us on X and LinkedIn.
